CompuGroup Medical SE & Co. KGaA

  • WKN: A28890
  • ISIN: DE000A288904
  • Land: Deutschland

Nachricht vom 14.09.2021 | 16:45

CompuGroup Medical SE & Co. KGaA announces medium-term targets for EBITDA-margin for the first time

CompuGroup Medical SE & Co. KGaA / Key word(s): Forecast
CompuGroup Medical SE & Co. KGaA announces medium-term targets for EBITDA-margin for the first time

14-Sep-2021 / 16:45 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

CompuGroup Medical SE & Co. KGaA ("CompuGroup Medical") announces medium-term targets for the development of the adjusted EBITDA-margin for the first time. The medium-term growth target of increasing group revenues year-on-year organically by 5 percent and more per year from 2021 through 2025 had been published previously. In addition, today the managing directors of the general partner CompuGroup Medical Management SE ("Managing Directors") have also concluded and adopted specific targets from the ongoing planning process with regard to the medium-term increase in adjusted EBITDA-margin for the first time. Accordingly, CompuGroup Medical aims to increase the adjusted EBITDA margin to approximately 25 % in 2023 and approximately 27 % in 2025. Further information on medium-term targets will be presented at tomorrow's virtual Capital Markets Day.

In light of the ongoing investment program announced in December 2020 to accelerate growth, the Managing Directors confirm the full year 2021 guidance. CompuGroup Medical expects revenues in 2021 to be in a range of € 1 billion and € 1.04 billion as well as adjusted EBITDA between € 210 million and € 230 million.

Explanation of financial figures:

The financial figure of adjusted operating profit (adjusted EBITDA) is not a figure defined in accordance with International Financial Reporting Standards (IFRS). It includes earnings before interest, taxes, depreciation and amortization, adjusted by the effects of major acquisitions and disposals of subsidiaries, business units and shareholdings, amortization as well as write-ups of shareholdings, effects from the acquisition, construction and sale of real estate, amortization and write-ups on owner-occupied real estate as well as expenses in connection with share-based compensation programs of the Managing Directors, as well as other non-operating or non-period-related non-recurring effects.

Adjusted EBITDA-margin is calculated by dividing adjusted EBITDA by group revenue.

Forward-Looking Statements

This release contains "forward-looking statements". Forward-looking statements may differ significantly from future results and often in fact differ. All forward-looking statements reflect CompuGroup Medical SE & Co. KGaA's ("CompuGroup Medical") current view on future events and are subject to risks relating to future events and other risks, uncertainties and assumptions regarding CompuGroup Medical's business, financial position, results of operations, liquidity, prospects, growth or strategy. Forward-looking statements should always be considered from the perspective of the date on which they are made. CompuGroup Medical as well as their affiliated companies expressly disclaim any obligation to update, review or adjust any forward-looking statements contained in this release as a result of new information, future developments or other reasons. Any responsibility for the future accuracy of the forward-looking statements expressed in this release or the actual occurrence of the forecast developments is expressly excluded.

14-Sep-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Linde Included in Dow Jones Sustainability World Index for 19th Consecutive Year

02. Dezember 2021, 12:00

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021